Maeda, Yuka
Wada, Hisashi https://orcid.org/0000-0002-5444-6193
Sugiyama, Daisuke https://orcid.org/0000-0003-1490-3211
Saito, Takuro
Irie, Takuma
Itahashi, Kota
Minoura, Kodai https://orcid.org/0000-0003-3221-329X
Suzuki, Susumu
Kojima, Takashi
Kakimi, Kazuhiro https://orcid.org/0000-0003-2631-3040
Nakajima, Jun
Funakoshi, Takeru
Iida, Shinsuke
Oka, Mikio
Shimamura, Teppei
Doi, Toshihiko
Doki, Yuichiro
Nakayama, Eiichi
Ueda, Ryuzo https://orcid.org/0000-0003-1120-1142
Nishikawa, Hiroyoshi https://orcid.org/0000-0001-6563-9807
Article History
Received: 7 September 2020
Accepted: 29 November 2021
First Online: 14 December 2021
Competing interests
: H.W. received research funding from Ono Pharmaceutical and Kyowa Kirin, and honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, MSD and Bristol-Myers Squibb outside of this study. Department of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine is a joint research laboratory with Shionogi & Co., Ltd. K.T. received honoraria and research funding from Ono Pharmaceutical, MSD, Shionogi, Bristol-Myers Squibb, Chugai Pharmaceutical, Amgen, Astellas Pharmaceutical, Oncolys BioPharma, Parexel and Merck Serono outside of this study. K.K. received research funding from TAKARA BIO and MSD outside of this study. Department of Immunotherapeutics, The University of Tokyo Hospital is endowed by TAKARA BIO. T.F. received research funding from Ono Pharmaceutical outside of this study. S.I. received honoraria and research funding from Ono Pharmaceutical, Takeda, Sanofi, Bristol-Myers Squibb, Janssen, Celgene and Daichi-Sankyo, and research funding from Kyowa Kirin, Abbvie, Chugai Pharmaceutical, MSD and Gilead outside of this study. M.O. received research funding from Thyas, Sysmex and Pole Star outside of this study. T.D. received honoraria and research funding from Lilly, Kyowa Kirin, MSD, Daiichi-Sankyo, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Novartis, Boehringer Ingelheim, Chugai Pharmaceutical, Bristol-Myers Squibb, Abbvie, and research funding from Merck Serono, Janssen Pharma, Pfizer, Quintiles, Eisai, and honoraria from Amgen, Takeda, Bayer, Rakuten Medical, Ono Pharmaceutical, Astellas Pharmaceutical, Oncolys BioPharma outside of this study. Y.D. received honoraria and research funding from Ono Pharmaceutical, Taiho Pharmaceutical, and research funding from Chugai Pharmaceutical, Covidien Japan, Jhonson & Jhonson and honoraria from Otsuka Pharmaceutical outside of this study. R.U. received research funding from Ono Pharmaceutical, Chugai Pharmaceutical and Kyowa Kirin outside of this study. H.N. received honoraria and research funding from Ono Pharmaceutical, Chugai Pharmaceutical, MSD and Bristol-Myers Squibb, and research funding from Taiho Pharmaceutical, Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debiopharma, Asahi-Kasei, Sysmex, Fujifilm, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma and BD Japan outside of this study. All other authors declare no competing interests.